Lineage Cell Therapeutics, Inc. Stock or Unit Option Plan Expense
Lineage Cell Therapeutics, Inc. (LCTX) reported Stock or Unit Option Plan Expense of $0 for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2012-03-14
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for the quarter ending 2011-12-31 was -$427.52K.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for the quarter ending 2011-09-30 was $141.32K, a 0.26% decline year-over-year.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for the quarter ending 2010-12-31 was -$313.33K.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for the quarter ending 2010-09-30 was $141.69K.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for fiscal 2011 was $0.00.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for fiscal 2010 was $0.00.
- Lineage Cell Therapeutics, Inc. stock or unit option plan expense for fiscal 2009 was -$483.69K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$427.52K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$286.19K derived: sum of 2 quarters · filed 2012-03-14 | $0.00 10-K · filed 2012-03-14 | |
| 2011-09-30 | $141.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $427.52K 10-Q · filed 2011-11-08 | ||
| 2011-06-30 | $286.19K 10-Q · filed 2011-08-09 | |||
| 2010-12-31 | -$313.33K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$171.63K derived: sum of 2 quarters · filed 2012-03-14 | $0.00 10-K · filed 2012-03-14 | |
| 2010-09-30 | $141.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $313.33K 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $171.63K 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | -$483.69K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |